anti-VEGFR2 (human), Rabbit Monoclonal (RM515)

Product description: Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not been previously described. A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (VEGFR-2) that encodes a secreted form of the protein, designated endogenous soluble VEGFR-2 (esVEGFR-2/KDR) has been described. The endogenous soluble esKDR inhibits developmental and reparative lymphangiogenesis by blocking VEGF-C function. Tissue-specific loss of esKDR in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Administration of esKDR inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring esKDR thus acts as a molecular uncoupler of blood and lymphatic vessels; modulation of esKDR might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema.

Alternate Names/Synonyms: Vascular Endothelial Growth Factor Receptor 2; Kinase Insert Domain Receptor; Protein-tyrosine Kinase Receptor Flk-1; CD309; KDR; FLK-1

Product Type: Recombinant Antibody

Clone: RM515

Isotype: Rabbit IgG

Immunogen: A peptide corresponding to residues near the C-terminus of human VEGFR2.

Applications: IHC, WB

Species Crossreactivity: Human

Specificity: This antibody reacts to human VEGFR2 (KDR; FLK-1; CD309).

Long Term Storage: -20°C

Shipping: BLUE ICE

Use & Stability: Stable for at least 1 year after receipt when stored at -20°C.

Lien vers la Fiche Technique